Abpro Bio International

Abpro is a clinical-stage biotechnology company focused on developing next-generation antibody therapeutics for severe diseases, with a primary emphasis on oncology and ophthalmology. The company leverages its proprietary DiversitAb and MultAb platforms to engineer bispecific antibodies that can engage multiple targets simultaneously, aiming to improve therapeutic outcomes over traditional monoclonal antibodies. Its lead candidate, ABP-100, is a bispecific antibody targeting HER2 and CD3 for the treatment of gastric and breast cancers. Abpro maintains a significant global presence through strategic partnerships and a public listing in South Korea via Abpro Bio Co., Ltd. The company is also advancing a pipeline of candidates for vascular eye diseases and other solid tumors.